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Introduction
Primary aldosteronism (PA) is a heterogeneous syndrome charac-
terized by hypertension, aldosterone overproduction and sup-
pressed plasma renin [1]. Spontaneous hypokalaemia was original-
ly regarded as a critical feature, but it is now known that most pa-
tients with PA are normokalaemic (63–91 %) [2]. The prevalence of 
PA is estimated as 6 % in the general population with hypertension 
[1], 11 % in patients referred to hypertension centres [3], and 
15–20 % in patients with resistant hypertension [4]. PA is now rec-
ognised as the most frequent form of endocrine hypertension with 
unilateral PA the most common surgically curable form of hyper-
tension.
Patients with PA display an elevated risk of cardiovascular and 
cerebrovascular diseases, target organ damage to the heart and 
kidney and metabolic alterations, including metabolic syndrome 
and diabetes [5–9], compared with patients with primary hyper-
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AbsTR AcT
The importance of an early diagnosis and appropriate manage-
ment of patients with primary aldosteronism (PA) has become 
increasingly clear because of the adverse impact of the disorder 
on cardiovascular and cerebrovascular events and target organ 
damage. Adrenalectomy potentially cures patients with unilat-
eral PA resulting in normalisation of blood pressure or signifi-
cant clinical improvements in the majority of patients. Different 
criteria have been used to evaluate outcomes of unilateral 
adrenalectomy. Clinical remission (cure of hypertension) is 
observed in 6 % to 86 % of patients and clinical benefits from 
surgery are seen in the majority. Several factors have been 
identified that predict clinical success after surgery such as age, 
sex, anti-hypertensive medication dosage and known duration 
of hypertension. Biochemical remission of PA after unilateral 
adrenalectomy, characterised by the resolution of hyperaldo-
steronism and correction of pre-surgical hypokalaemia, is ob-
served in 67 % to 100 % of patients with unilateral PA. In only a 
small proportion of patients, adrenalectomy fails to resolve 
hyperaldosteronism and inappropriate aldosterone production 
persists after surgery. In this review we discuss the potential 
reasons for failing to cure hyperaldosteronism after unilateral 
adrenalectomy for unilateral primary aldosteronism.
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tension with matched cardiovascular risk profiles [10]. These det-
rimental effects are caused by the excessive secretion of aldoster-
one and a potential role for glucocorticoid overproduction has also 
been reported [8, 11]. PA is also associated with psychological 
symptoms such as anxiety and depression with a negative impact 
on quality of life [12, 13]. Therefore, an early diagnosis and specif-
ic treatment of unilateral and bilateral PA is essential.
The diagnostic work-up of PA is recommended by the Endocrine 
Society’s Clinical Guideline and begins with the screening for inap-
propriately elevated aldosterone production relative to suppressed 
plasma renin levels (aldosterone-to-renin ratio, ARR) in most pa-
tients with hypertension except those with mild hypertension [14]. 
Patients with a positive ARR test proceed to confirmation testing 
(including oral sodium loading, saline infusion, fludrocortisone sup-
pression, and captopril challenge) and finally subtype differentia-
tion of unilateral from bilateral PA (including adrenal venous sam-
pling (AVS) and computed tomography (CT) scanning) [15]. The 
clinical management of PA depends on subtype differentiation: 
mineralocorticoid receptor (MR) antagonists for patients with bi-
lateral PA, and unilateral adrenalectomy for patients with unilater-
al forms (including unilateral aldosterone producing adenomas 
(APA) and unilateral adrenal hyperplasia) [15].
Laparoscopic adrenalectomy is the recommended surgical 
treatment option due to the associated low morbidity (5–14 %), 
mortality well below 1 % and short hospital stays of usually 3 days 
[16]. Surgical resection of the hyperfunctioning adrenal potential-
ly normalises blood pressure (BP) and should reverse the detrimen-
tal effects of hormonal excess [13, 16–18]. Clinical improvements, 
with significant post-surgical reductions in blood pressure, are ob-
served in most patients such that a clinical benefit (complete clin-
ical success [clinical remission] or partial clinical success [clinical 
improvement]) is achievable in over 4 out of every 5 patients [18]. 
Reasons contributing to the absence of clinical remission include 
the presence of background primary hypertension, long-standing 
hypertension, older age, renal insufficiency or other co-morbidities 
[19–24]. In contrast, biochemical remission with cure of hyperal-
dosteronism and normalisation of spontaneous hypokalaemia (if 
present pre-surgically) should be achieved in all patients with a cor-
rect diagnosis of unilateral PA and surgically successful total adre-
nalectomy. Despite this, in a recent multicentre international co-
hort study, persistent biochemical aldosteronism after adrenalec-
tomy was observed in 6 % of 699 patients with a diagnosis of 
unilateral PA by AVS [18]. In this manuscript, we review outcomes 
after adrenalectomy and possible reasons for incomplete biochem-
ical remission after total adrenalectomy, summarised in ▶Table 1.
Surgical and Medical Management of PA
Adrenalectomy has a low frequency of major complications (1.3 %) 
[25] and is associated with a high proportion of patients achieving 
biochemical remission [16, 18, 26–28]. Several studies report sig-
nificant improvements in quality of life in patients treated surgi-
cally rather than medically [29–31]. Patients with medical manage-
ment have worse quality of life scores (measured by Medical Out-
comes Study Short Form 36 General Health Survey) with increased 
depression and anxiety compared with patients with surgical treat-
ment [29, 30, 32]. A prospective study identified increased benefi-
cial effects of surgical treatment compared with medical manage-
ment on patient quality of life, with a health-related quality of life 
almost comparable with that of the general population [31]. This 
may be related to continued hormone excess in patients with med-
ical treatment which may still affect mood-regulating areas of the 
brain, and cortisol co-secretion from an APA may impair psycho-
logical well-being [33].
A study that compared ten-year follow-up between 602 patients 
initiated on MR antagonists and 41,853 age-matched patients with 
primary hypertension demonstrated doubling the incidence of car-
diovascular events in patients with PA treated with MR antagonists, 
despite comparable blood pressure levels [34]. The risks of incident 
diabetes, atrial fibrillation, and mortality were also increased in pa-
tients with MR antagonist treatment. The adverse cardiometabol-
ic outcomes of patients with PA treated with MR antagonists was 
limited to patients with sustained renin activity suppression 
( < 1 µg/L/h), therefore the study highlighted the importance of op-
timal titration of MR antagonist dosage and long-term follow-up 
with monitoring of biochemical parameters [34]. The comparison 
of kidney function between surgically and medically treated pa-
tients with PA reported a decrease in GFR and albumin excretion 
with surgical treatment compared with medical treatment with 
low-dose spironolactone (50 mg/day) [35, 36]. Moreover, a large 
▶Table 1 Treatment of unilateral PA by adrenalectomy: potential reasons for incomplete biochemical cure.
Adrenalectomy of 
non-dominant  
(contralateral) adrenal
Subtype differentiation by CT scanning:
1) lacks sensitivity to detect micro-APAs < 10 mm in diameter
2)  lack of functional information can result in resection of incidentaloma instead of source of aldosterone production
Subtype differentiation by AVS:
1) influence of protocol: 
–  sequential unstimulated AVS could result in artificial gradients between adrenal glands in prolonged procedures
2) interpretation of results: 
– less strigent criteria for SI and LI can compromise diagnostic accuracy
Adrenalectomy of 
dominant (ipsilateral) 
adrenal
Bilateral PA with asymmetrical production of aldosterone can potentially give an AVS result of unilateral PA.
APA, aldosterone-producing adenoma; ACTH, adrenocorticotropic hormone; AVS, adrenal venous sampling; CT, computed tomography; LI, 
lateralisation index; PA, primary aldosteronism; SI, selectivity index; Potential reasons for failing to cure hyperaldosteronism after adrenalectomy for 
unilateral PA are shown. These include adrenalectomy on the wrong side resulting from limitations of CT scanning (lack of sensitivity and functional 
information) and AVS (influence of protocol and interpretation of results) or adrenalectomy of ipsilateral adrenal in patients with bilateral PA with 
asymmetrical production of aldosterone.
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prospective study that assessed long-term cardiovascular out-
comes and mortality with a median of 11.8 years follow-up report-
ed a higher potential of atrial fibrillation and lower atrial fibrillation-
free survival in medically treated patients [37]. In contrast, the 
long-term outcomes of surgically treated patients were similar to 
those of patients with primary hypertension [37].
Post-Operative Outcomes of Adrenalectomy 
for Unilateral PA
Surgical management of unilateral PA resolves the biochemical ab-
normalities such as elevated aldosterone production, abnormal 
ARR and hypokalaemia (if present pre-surgically) in 67 %-100 % of 
patients [16, 18, 26–28, 38]. For clinical outcomes, the proportion 
of patients achieving cure of elevated blood pressure is highly var-
iable, ranging from 6 % to 86 %, with an improvement reported in 
14 %-85 % of patients [13, 16, 18, 26–28, 38]. A decrease in systolic 
BP of 25 to 40 mmHg and a reduction in antihypertensive medica-
tion dosage (1–2 drug classes) have been reported after adrenal-
ectomy for unilateral PA [38, 39]. A reduction in left ventricular hy-
pertrophy has also been reported at short-term and long-term fol-
low-up [40]. Glomerular hyperfiltration (an increased glomerular 
filtration rate (GFR) and decreased urinary albumin excretion) is re-
versible by surgery [35, 41, 42] (▶Table 2).
The above studies used diverse diagnostic procedures, different 
criteria and duration of follow-up to assess post-surgical outcomes. 
The PASO (primary aldosteronism surgical outcome) study [18] es-
tablished a set of internationally standardised criteria for outcome 
assessment in which outcomes were defined as complete (cure or 
remission), partial (improvement) and absent (failure) clinical or 
biochemical success with outcome assessment at 6–12 months. 
These criteria were then used to assess outcomes in an internation-
al multicentre cohort of 705 patients with subtype diagnosis by 
AVS. Biochemical remission classified as normalisation of plasma 
potassium (if hypokalaemia was present pre-surgery) and of the 
ARR was achieved in 94 % of patients, with the remaining patients 
▶Table 2 Cardiometabolic events and target organ damage in unilateral PA versus essential hypertension at diagnosis and follow-up after unilateral adre-
nalectomy.
cardiometabolic Events and Target 
Organ Damage
Diagnosis FU FU 
Interval
Reference
Unilateral PA EH Unilateral PA EH
Stroke and/or TIA 24/224 (11 %) 12/224 (5 %) [81]
3/29 (10 %) 9/323 (3 %) [9]
7/57 (12 %) 5/171 (3 %) 3/57 (5 %) 2/171 (1 %) 12 y [5]
0/41 (0 %) 0/894 (0 %) 1/34 (3 %) 7/700 (1 %) 11.8 y [37]
CAD (MI and/or Reversible Ischemia) 4/224 (2 %) 9/224 (4 %) [81]
6/29 (21 %) 27/323 (8 %) [9]
3/57 (5 %) 4/171 (2 %) 1/57 (2 %) 3/171 (2 %) 12 y [5]
0/41 (0 %) 0/894 (0 %) 1/34 (3 %) 26/684 (4 %) 11.8 y [37]
Arrhythmias 5/29 (17 %) 11/323 (3 %) [81]
5/57 (9 %) 1/171 (0.6 %) 1/57 (2 %) 3/171 (2 %) 12 y [5]
2/41 (5 %) 2/894 (0.2 %) 2/35 (6 %) 20/667 (3 %) 11.8 y [37]
Heart Failure 8/224 (4 %) 9/224 (4 %) [81]
1/57 (2 %) 1/171 (0.6 %) 2/57 (4 %) 0/171 (0 %) 12 y [5]
0/41 (0 %) 0/894 (0 %) 2/35 (6 %) 10/667 (2 %) 11.8 y [37]
LVH 9/24 (38 %) 24/108 (22 %) 2/24 (8 %) 9/108 (8 %) 6.4 y [82]
67/110 (61 %) 76/143 (53 %) 50/110 (46 %) 61/143 (43 %) 3 y [40]
17/26 (65 %) 390/1229 (32 %) [1]
PAD 2/29 (7 %) 8/323 (2 %) [9]
Metabolic Syndrome 11/37 (30 %) 39/192 (20 %) [83]
6/9 (67 %) 4/11 (36 %) 5/9 (56 %) NA 6 m [84]
12/27 (44 %) 441/1478 (30 %) [1]
Diabetes 11/50 (22 %) 20/90 (22 %) [85]
0/27 (0 %) 55/1414 (4 %) [1]
Microalbuminuria 6/21 (29 %) 150/1168 (13 %) [1]
CAD, coronary artery disease; EH, essential hypertension; FU, follow-up; LVH, left ventricular hypertrophy; m, months; MI, myocardial infarction; NA, 
not available; PA, primary aldosteronism; PAD, peripheral arterial disease; TIA, transient ischaemic attack; y, years. Values indicate numbers of 
patients with cardiometabolic events or target organ damage divided by total number of patients with the proportion of affected patients in 
parenthesis; The incidence of cardiometabolic events and target organ damage are shown for patients with unilateral PA compared with patients with 
essential hypertension at diagnosis and follow-up after adrenalectomy. The cardiometabolic events and target organ damage include stroke and/or 
transient ischaemic attack, coronary artery disease, arrhythmias, heat failure, left ventricular hypertrophy, peripheral arterial disease, metabolic 
syndrome, diabetes, and microalbuminuria.
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comprising those with partial biochemical success (4 %) and those 
with absent success (2 %). In contrast, the proportion of patients 
with complete clinical success (cure of hypertension) was 37 %, with 
47 % of patients attaining significant clinical improvements. Female 
sex and younger age were associated with clinical benefit (com-
plete  +  partial clinical success) with sex and age contributing to 
the diverse between-centre clinical outcomes. Miller et al., evalu-
ated the PASO standards against other outcome criteria and re-
ported an improvement in the definition of short- and long-term 
post-surgical outcomes with the PASO consensus [28].
Post-Surgical Persistent Hyperaldosteronism: 
Differentiation of Unilateral from Bilateral PA 
by Adrenal CT Scanning
Subtype	differentiation	by	adrenal	CT	scanning
The successful treatment by adrenalectomy is dependent on the 
accurate differentiation of unilateral from bilateral PA. The most 
widely diffuse approach for subtype determination is CT or mag-
netic resonance imaging (MRI) of the adrenals to detect morpho-
logical alterations followed by AVS in centres where it is available. 
The Endocrine Society’s Clinical Guideline recommends adrenal CT 
on all patients with confirmed PA [14] to exclude adrenal carcino-
mas that are usually > 40 mm in diameter and differ in densitome-
try from adenomas [43, 44]. CT scanning also helps delineate the 
anatomy of adrenal veins to aid positioning of catheters in AVS. 
However, the sensitivity of CT is often inadequate for detection of 
micro-APAs < 10 mm in diameter, and an APA can display like small 
hypodense (normally lower than 10 HU) nodules on unenhanced 
CT due to its high component of intracellular lipid [14, 44]. There-
fore, small APAs can be undetectable on CT, or can be misinterpret-
ed by radiologists as idiopathic hyperaldosteronism when coinci-
dently detecting bilateral nodularity or normal-appearing adrenals 
[14]. Moreover, CT cannot provide functional information on al-
dosterone secretion. Non-functioning adenomas (or incidentalo-
mas) share a similar morphology to APA on CT and are difficult to 
differentiate, which is a problem compounded in older individu-
als > 35 years old who more frequently have incidentalomas [45]. 
Thus, inappropriate adrenalectomy of a functionally normal adre-
nal can occur if solely relying on CT scanning.
Performance	of	adrenal	CT	scanning	compared	 
with	AVS
A number of studies have compared adrenal imaging with AVS for 
the accuracy of lateralisation with some studies assessing the his-
tology of the resected adrenal. Gordon RD et al., [46] reported cor-
rect CT lateralisation in around half (59/111) of patients and < 25 % 
in patients with an APA < 10 mm in diameter, and a report from the 
Mayo Clinic showed that unnecessary adrenalectomies could occur 
in 25 % of patients whilst 22 % of patients could miss the chance of 
surgery [17]. In a systematic review, the proportion of patients with 
a misdiagnosis of PA subtypes was approximately 40 % when rely-
ing on CT and MRI alone by comparison with AVS results as the ref-
erence standard [47]. A study comparing imaging and AVS results 
in 263 patients revealed that adrenal imaging and AVS were con-
cordant to the surgically documented side in 58.6 % and 97.1 % of 
patients, respectively [27]. Another study included 175 patients 
who underwent unilateral adrenalectomy reported the accuracy 
of CT as 57.3 % for detecting unilateral PA, with 12.2 % of contralat-
eral (non-dominant) side of lateralisation and 22 % of false diagno-
sis of bilateral PA, while AVS results could prove unilateral aldoster-
one hypersecretion correctly [48]. A recent study compared AVS 
with CT data in patients with unilateral PA (diagnosed by AVS) and 
biochemical cure at follow-up and indicated that imaging and AVS 
results were concordant in 64 % of 491 patients with 34 % of pa-
tients showing bilateral normal or bilateral abnormal results by CT 
scanning and 2 % of patients with unilateral abnormal imaging of 
the contralateral adrenal [49]. All these studies therefore indicated 
the superior performance of AVS to CT and MRI techniques for sub-
type differentiation of PA. However, a restricted subgroup of pa-
tients can bypass AVS using predictors of younger age and marked 
phenotype of PA [14]. A high accuracy (100 %) of CT scanning has 
been demonstrated for lateralisation in PA with a large nod-
ule > 10 mm in diameter with normal appearance of the contralat-
eral gland in young patients (aged < 35 years) with spontaneous 
hypokalaemia and marked aldosterone excess at baseline [49, 50]. 
A high accuracy (87 %) was also noted in patients aged 35–40 years 
with evident symptoms [50]. Therefore, with the exception of 
young patients with a specific phenotype, most retrospective stud-
ies indicate that CT imaging is not as reliable as AVS for accurate 
subtype differentiation in PA.
A recent randomized prospective trial compared the treatment 
outcomes in patients with CT- and AVS-based management and 
challenged the reference standard status of AVS [51]. A total of 184 
patients with florid PA were randomly assigned to CT-based and 
AVS-based treatments and outcomes were assessed at one year of 
follow-up. The study reported no differences in antihypertensive 
medication dosage (median 3.0 vs 3.0), normalisation of target 
blood pressure (42 % vs 45 %), and medians of RAND-36 physical or 
mental score (52.7 vs 53.2) between two groups and concluded 
that CT or AVS management did not result in significant differenc-
es in clinical benefits after one-year follow-up. Biochemical remis-
sion was 80 % with CT-based management (vs 89 % in AVS-based 
management) [51]. Similar conclusions were also made by a retro-
spective study that reported comparable follow-up blood pressures 
in 109 patients with CT-based and 59 patients with AVS-based ad-
renalectomy [52]. The prospective clinical trial was criticised for 
being underpowered with a non-representative study cohort due 
to inclusion of fewer females and florid PA that can predict persis-
tence of high blood pressure due to target organ damage. The use 
of cosyntropin in the AVS procedure was also criticised because this 
can confound or even invert lateralisation thereby indicating adre-
nalectomy on the wrong side [53]. A retrospective assessment of 
the post-surgical outcomes of 761 patients treated by unilateral 
adrenalectomy for unilateral PA (235 and 526 patients with a sur-
gical approach based on CT or AVS, respectively) in accordance with 
the PASO criteria reported that CT-based surgical management was 
a predictor of a decreased likelihood of complete biochemical suc-
cess, and was associated with inappropriate post-surgical aldoster-
one production and absent clinical success [49].
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Post-Surgical Persistent Hyperaldosteronism: 
Differentiation of Unilateral from Bilateral PA 
by Adrenal Venous Sampling
Influence	of	AVS	protocol:	unstimulated	versus	ACTH	
stimulated	AVS
Adrenocorticotropic hormone (ACTH) levels fluctuate in a diurnal 
pattern and increase when the hypothalamic-pituitary-adrenal axis 
is activated by emotional and pain-related stress thereby affecting 
both aldosterone and cortisol secretion. AVS can employ ACTH (1–
24) (cosyntropin, a synthetic derivative of ACTH that contains the 
first 24 amino acids but maintains full function) stimulation by ei-
ther constant cosyntropin infusion (50 µg/h, started 30 min before 
AVS) or by bolus (usually 0.25 mg) [54].
ACTH-stimulated AVS enhances the selectivity index (SI, ratio 
of concentrations of cortisol from an adrenal vein and a peripheral 
vein) by maximising the cortisol gradients between adrenal and 
peripheral veins, thereby increasing success rates of sampling which 
especially benefits less experienced radiologists [55]. Because 
ACTH minimizes cortisol fluctuations, AVS with sequential cathe-
terisation can be performed [55]. Furthermore, additional cortisol 
secretion provides steroid prophylaxis for patients with high risks 
of allergic reaction. By contrast, unstimulated AVS requires addi-
tional patient management. Without cosyntropin stimulation, pa-
tients are suggested to be sustained in the supine position for one 
hour before AVS which should be performed in the early morning 
when the ACTH secretion is highest to avoid false-negative results 
[56]. Besides, measures solving emotion- and pain-related stress 
should be adopted such as reassurance from doctors, administration 
of benzodiazepines and local anesthesia [55, 57]. Unstimulated AVS 
should also require bilateral simultaneous catheterisation [58].
Studies that compared unstimulated with ACTH-stimulated AVS 
highlighted the potential pitfalls introduced by ACTH stimulation. 
It not only increases aldosterone production from APAs, but will 
also stimulate aldosterone secretion from the contralateral adre-
nal, thereby potentially reducing the lateralisation index (LI, aldos-
terone concentrations divided by the respective cortisol concen-
trations between adrenal veins) and introducing the possibility of 
a false diagnosis of bilateral PA [58]. A multicentre study that com-
pared basal and ACTH stimulated AVS (by ACTH infusion or bolus) 
reported a significant increase in SI especially after ACTH bolus but 
no differences in LI between the two approaches. The discordant 
diagnoses between basal and post-ACTH conditions ranged from 
17 % to 36 % depending on the criteria, with the more stringent cri-
teria contributing to the higher reproducibility of diagnosis [59]. 
Another study with 171 patients with AVS performed before and 
after ACTH bolus found a discordance in subtype diagnosis of 28 %, 
most of which were lateralized cases under basal conditions that 
were diagnosed as bilateral after ACTH stimulation [60]. A higher 
rate (91 %) of concordant diagnoses was obtained by Wolley et al. 
[61], in which one unilateral case was diagnosed as bilateral and 
two bilateral cases became unilateral after ACTH stimulation.
Hence, ACTH-stimulated AVS is useful to reduce non-diagnos-
tic cases, allows sequential catheterisation, and benefits patients 
with an allergic reaction or when AVS cannot be performed in the 
morning. However, there is a potential to confound lateralisation 
results and therefore the protocol requires the optimization of di-
agnostic criteria.
Influence	of	AVS	protocol:	simultaneous	
unstimulated	versus	sequential	unstimulated	AVS
Oscillations of aldosterone and cortisol secretion can produce ar-
tificial gradients between adrenal glands if AVS is performed se-
quentially under basal conditions. This is circumvented by simulta-
neous cannulation but the possibility of adrenal vein thrombosis is 
increased because the procedure requires obstruction of vessel 
lumen by the catheter until achieving successful cannulation of the 
contralateral vein. Consequently simultaneous bilateral AVS is more 
invasive and technically demanding and there is an inverse corre-
lation of the rate of complications and the number of AVS per-
formed by radiologists [62].
A study investigating the effect of stress on SI alterations during 
sequential and simultaneous AVS demonstrated that the SI from 
sequential AVS is higher than with simultaneous AVS, indicating 
differences of selectivity between the two methods of cannulation 
[63]. However, in the PASO study, the Brisbane group used a se-
quential unstimulated AVS approach with no absent biochemical 
success cases, which argues against important fluctuations of lat-
eralisation of gradients due to stress or pulsatile secretion [18]. 
Moreover, a retrospective study compared simultaneous and se-
quential unstimulated AVS in 188 patients. Bilateral simultaneous 
AVS were obtained twice within five minutes, whilst sequential AVS 
was performed with a time-gap of 5 min between the two cathe-
terisations. No significant difference was recorded in terms of the 
SI and LI values between simultaneous and sequential AVS and be-
tween two repeated simultaneous AVS. It suggested no superior-
ity of simultaneous over sequential AVS under basal conditions if 
catheterisation of two adrenal veins can be achieved within five 
minutes [64].
Therefore, there is no consensus on the better performance of 
simultaneous or sequential unstimulated AVS, but the two ap-
proaches have a similar accuracy when performed by skilled and 
experienced radiologists if the sequential approach is performed 
in a short time interval. However, simultaneous unstimulated AVS 
is more likely to be preferred, considering potential fluctuations of 
aldosterone and cortisol during sequential catheterisation in an 
unstimulated AVS procedure.
Interpretation	of	AVS	results
AVS results are interpreted by calculating several indexes based on 
aldosterone and cortisol concentrations in the adrenal or periph-
eral veins, and the cut-offs employed define the diagnosis.
SI is used to confirm adequate cannulation of adrenal veins on 
the assumption that cortisol is exclusively produced from adrenals 
and is not overproduced by an APA. No consensus has been reached 
on the criteria for successful catheterisation. The cut-offs of the SI 
vary among referral centres, ranging from 1.1 to 3 under basal con-
ditions and 2 to 5 with ACTH stimulated AVS [65]. Expert recom-
mendations for SI cut-offs have been proposed as ≥ 2 for unstimu-
lated AVS, and  ≥ 3.0 for AVS with ACTH stimulation [55], and > 3 
under basal conditions and > 5 in ACTH stimulated AVS [54]. Most 
centres adopt SI > 2 to 3 in basal conditions and > 3 to 5 with ACTH 
stimulation [66], and considerable disparities in diagnosis are 
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reached using less stringent criteria for successful cannulation. A 
study compared the influences of permissive (SI ≥ 1.1), intermedi-
ate (SI ≥ 2) and strict (SI ≥ 3) criteria on subtype diagnosis in unstim-
ulated AVS. Permissive criteria achieved the highest success rate of 
bilateral cannulation (91 %), while the proportion of concordant di-
agnoses was decreased to 35 % between the first and second AVS. 
It was proposed that an SI cut-off of  ≥ 2.75 is necessary for diag-
nostic reproducibility [67]. These three criteria were compared 
again under basal AVS. It showed that the permissive cut-off values 
were associated with the lowest specificity (76.9 %) and highest 
sensitivity (98.5 %) for selectivity, whilst the strict criteria guaran-
teed 100 % specificity but compromised sensitivity (50.4 %). A SI 
cut-off of 2 was finally recommended by this study to gain best sen-
sitivity (70.8 %) and 100 % specificity [68]. To identity the most ac-
curate criteria for AVS, a study analysed 10 reported AVS criteria 
from the literature in a cohort of 108 patients with PA. An SI > 5 was 
the most accurate with 88 % true positives and an SI > 1.1 was accu-
rate without ACTH stimulation [65]. Thus, a lower SI chosen for se-
lective cannulation can increase the proportion of patients referred 
to lateralisation, but potentially compromise diagnostic accuracy 
with an impact on biochemical outcomes after adrenalectomy.
The assessment of lateralization of aldosterone hypersecretion 
depends on the LI. Inclusion of cortisol concentrations from adre-
nal veins aims to correct for the level of adrenal aldosterone in case 
inevitable dilution by non-adrenal blood affects their concentra-
tions. The cut-off values for the LI used in referral centres vary widely. 
Most units use an LI ≥ 4 for the diagnosis of unilateral PA, though 
some centres accept more permissive criteria (LI ≥ 3 or LI ≥ 2). More 
restrictive LI thresholds lead to lower rates of diagnosis of unilat-
eral PA [67], but is more likely to select a population to be cured 
with adrenalectomy [55]. An LI cut-offs of 4 and 2 has been recom-
mended for ACTH-stimulated AVS and unstimulated AVS respec-
tively [55]. An LI ≥ 4 with ACTH stimulation was recommended by 
another report which considered LI < 3 to be diagnostic of BAH with 
3–4 a grey zone [54]. The importance of using stringent LI was later 
highlighted by a study investigating LI from patients with hyper-
tension with PA excluded. Lateralization gradients between 2 and 
4 were found in 20 % of patients with negative confirmatory test for 
PA, with LIs ranging from 1.01 to 3.87 [69].
Additional indexes are used in some units to replace or strength-
en LI results for lateralisation. The utility of the ipsilateral ratio (ILR), 
the ratio between the aldosterone/cortisol level on the dominant 
side and that level in peripheral vein, together with contralateral 
ratio (CLR), the ratio between the aldosterone/cortisol level in con-
tralateral adrenal vein and that level in peripheral vein, were inves-
tigated. ILR > 2 and CLR < 1 were regarded by some centres as a use-
ful criterion for unilateral PA [70]. Other studies displayed a lack of 
effect of contralateral aldosterone suppression on outcomes of sur-
gically treated patients with PA [71, 72]. Absolute contralateral al-
dosterone ratio that is aldosterone concentration in the contralat-
eral adrenal vein divided by that in peripheral vein were set with a 
cut-off of 1.5 to predict outcomes after adrenalectomy [60]. An-
other use of aldosterone concentration is the absolute aldosterone 
concentration that indicates the hyperfunctioning side with aldos-
terone > 38780 pmol/L [73]. All these indexes are less utilized, but 
they can influence the cure rate after adrenalectomy in centres 
using and interpreting them.
Can	AVS	fail	if	it	has	been	appropriately	performed	
and	interpreted?
AVS is however not perfect. Bilateral PA with asymmetrical produc-
tion of aldosterone will potentially present an AVS result of unilat-
eral PA when the LI exceeds the stringent cut-off of 4. AVS can also 
give misleading results when patients with PA have concurrent sub-
clinical Cushing’s syndrome because the SI would indicate unsuc-
cessful cannulation [74]. Patients with a successful AVS with a strin-
gent LI (ranging from 4.4 to 10.0) still result in absent biochemical 
outcomes in some cases [18]. Thus, AVS cannot guarantee success 
even if it has been appropriately performed and interpreted.
Conclusions and Perspectives
Some patients with unilateral PA are not cured of persistent hyper-
aldosteronism after unilateral adrenalectomy. Focus should there-
fore be placed on minimizing such failures, which can be derived 
from inaccurate differentiation of unilateral from bilateral PA by ei-
ther CT scanning or AVS. Future approaches to lateralise aldoster-
one production may replace or be used in conjunction with tradi-
tional methods and may minimise post-surgical biochemical per-
sistence. Functional molecular imaging approaches using the 
CXCR4 ligand 68Ga-pentixafor may visualise the hypersecreting 
adrenal [75] as well as other functional imaging methods such as 
11C-metomidate positron emission tomography-CT imaging and 
(6β-131I) iodomethyl-19-norcholesterol scan [14]. Other ap-
proaches include potentially reducing the numbers of patients that 
undergo AVS by selecting patients with an APA by mass spectrom-
etry-based peripheral venous steroid profiling [76, 77] or using 
macrolide antibiotics that selectively inhibit aldosterone hyperse-
cretion from APAs carrying KCNJ5 mutations [78–80].[40, 81–85]
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